<DOC>
	<DOCNO>NCT01262898</DOCNO>
	<brief_summary>GSK962040 novel small molecule motilin agonist . The Phase I study ( MOT107043 MOT109681 ) demonstrate single dos GSK962040 150 mg repeat dose 125 mg/day 14 day well tolerated adverse event occur great prevalence placebo , significant abnormal vital sign , ECG , clinical laboratory finding . Pharmacokinetic parameter linear approximately dose proportional range dos administer . Single dose 50 mg - 150 mg GSK962040 significantly increase rate gastric empty 40 % measure 13C octanoic acid stable isotope breath test . A similar effect 50 mg 125 mg gastric empty observe throughout repeat dose healthy volunteer 14-days . The aims present investigation ( MOT114479 ) ass pharmacodynamic effect ( gastric empty symptom ) , safety , tolerability , pharmacokinetics GSK962040 28 day once-daily dose Type I Type II diabetic subject gastroparesis . An additional aim characterize dose/exposure - pharmacodynamic effect relationship .</brief_summary>
	<brief_title>Dose Response 28 Days Dosing GSK962040 Type I II Diabetic Male Female Subjects With Gastroparesis</brief_title>
	<detailed_description />
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>Type I II Diabetes Mellitus ( HbA1C &lt; 10 % ) Male female 18 80 year age , inclusive . Patient gastroparesis screening ( gastric halftime empty &gt; upper limit normal determine 13Coral breath test ) Patient must &gt; = 3 month history relevant symptom gastroparesis ( e.g. , chronic postprandial fullness , early satiety , postprandial nausea ) , patient mean daily score minimum 7 day indicate &gt; = mild ( 2 ) &lt; = severe ( 4 ) postprandial fullness assess use GCSIDD screening period prior randomization . A female patient eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/mL , value consistent local laboratory standard value , confirmatory . OR Childbearing potential agrees use one contraception method list Section 8.1 appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female patient must agree use contraception least 5 day follow last dose study medication . Male patient must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication least 5 day last dose study medication . BMI &gt; 18 &lt; = 35.0 kg/m2 ( inclusive ) . Patient never gastrectomy , major gastric surgical procedure evidence bowel obstruction stricture within previous 12 month Dosage concomitant medication stable least 3 week , except routine adjustment daily insulin treatment . Estimated ( measure ) glomerular filtration rate &gt; = 30 mL/min . QTcB QTcF &lt; 450 msec QTc &lt; 480 msec patient Bundle Branch Block base single average QTc value triplicate value obtain brief recording period . Capable give write informed consent , include compliance requirement restriction list consent form . AST ALT &lt; 2xULN ; alkaline phosphatase bilirubin &lt; = 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Patient acute severe gastroenteritis Patient gastric pacemaker Patient chronic parenteral feeding Patient pronounce dehydration Recent ( last 6 week ) history poor control diabetes e.g . hypoglycaemia require medical intervention , diabetic ketoacidosis , admission control diabetes complication diabetes Patient evidence severe cardiovascular autonomic neuropathy ( e.g . history recurrent syncope last 6 month ) Patient history eat disorder ( anorexia nervosa , binge eating , bulimia ) Use medication potentially influence upper gastrointestinal motility appetite within one week study ( e.g. , prokinetic drug , macrolide antibiotic ( erythromycin ) , GLP1 mimetics ) Regular opiate use Use prohibit medication list Section 9.2 within restrict timeframe relative first dose study medication . History presence clinically significant gastrointestinal , hepatic renal disease condition would opinion investigator medical monitor make subject unsuitable inclusion clinical study . The patient participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day timeperiod . Pregnant female determine positive serum urine hCG test ( first urine day ) screen prior dosing . Lactating female . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>13 C oral breath test</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>symptom</keyword>
	<keyword>tolerability</keyword>
	<keyword>gut motility</keyword>
	<keyword>repeat dose</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>GSK962040</keyword>
	<keyword>phase II</keyword>
	<keyword>Type I II Diabetes mellitus</keyword>
	<keyword>gastric empty</keyword>
	<keyword>gastroparesis</keyword>
</DOC>